Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen

International Journal of Cancer

Volumn 99, Issue 2, 2002, Pages 201-206

  Wirth, Susanne ^a   Bille, Frédéric ^a   Koenig, Sylvain ^a   Wehrli, Nathalie ^a   Miconnet, Isabelle ^a   Lévy, Frédéric ^a   Diggelmann, Heidi ^a   Romero, Pedro ^a   Acha Orbea, Hans ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cytotoxic T lymphocyte; Mouse mammary tumor virus; Superantigen; Tumor immunology; Vaccinia virus

Indexed keywords

CD4 ANTIGEN; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EMBRYO; HUMAN; HUMAN CELL; INJECTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HLA-A ANTIGENS; LUMINESCENT PROTEINS; MAMMARY TUMOR VIRUS, MOUSE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINIA VIRUS;

EID: 0037052647     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10237     Document Type: Article

References (34)

1. Tumor antigens recognized by T lymphocytes
2. Paracrine cytokine adjuvants in cancer immunotherapy
3. Dendritic cell vaccines for cancer immunotherapy
4. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules
5. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
6. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gpl00 modified at HLA-A*0201-binding residues
7. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
8. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
9. Cancer vaccine design: A novel bacterial adjuvant for peptide-specific CTL induction
10. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue
11. + T cell response depending on the route of immunization
12. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
13. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
14. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
15. + cytotoxic T lymphocytes
16. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
17. b transgenic mice
18. Mouse mammary tumor virus: Immunological interplays between virus and host
19. Infection breaks T-cell tolerance
20. Rabies superantigen as a Vbeta T-dependent adjuvant
21. Stimulation with specific antigen can block superantigen-mediated deletion of T cells in vivo
22. Early neutralizing antibody response against mouse mammary tumor virus: Critical role of viral infection and superantigen-reactive T cells
23. Human T cells respond to mouse mammary tumor virus-encoded superantigen: Vbeta restriction and conserved evolutionary features
24. In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen
25. Bystander virus infection prolongs activated T cell survival
26. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
27. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
28. New insights into the mobilization and phagocytic activity of dendritic cells
29. Production of high-titer helper-free retroviruses by transient transfection
30. Species-restricted interactions between CD8 and the alpha3 domain of class I influence the magnitude of the xenogeneic response
31. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light
32. Using ubiquitin to follow the metabolic fate of a protein
33. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3
34. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation